Glycoengineering Human Neural and Adipose Stem Cells with Novel Thiol-Modified N -Acetylmannosamine (ManNAc) Analogs.
Du J., Agatemor C., Saeui CT., Bhattacharya R., Jia X., Yarema KJ.
Laboratory Study, published in Cells (2021) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Cells (2021)
- Country
- Switzerland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 33673061
- PMCID
- PMC7918483
- DOI
- 10.3390/cells10020377
- Citations
- 13
Abstract (original English)
This report describes novel thiol-modified N -acetylmannosamine (ManNAc) analogs that extend metabolic glycoengineering (MGE) applications of Ac 5 ManNTGc, a non-natural monosaccharide that metabolically installs the thio-glycolyl of sialic acid into human glycoconjugates. We previously found that Ac 5 ManNTGc elicited non-canonical activation of Wnt signaling in human embryoid body derived (hEBD) cells but only in the presence of a high affinity, chemically compatible scaffold. Our new analogs Ac 5 ManNTProp and Ac 5 ManNTBut overcome the requirement for a complementary scaffold by displaying thiol groups on longer, N -acyl linker arms, thereby presumably increasing their ability to interact and crosslink with surrounding thiols. These new analogs showed increased potency in human neural stem cells (hNSCs) and human adipose stem cells (hASCs). In the hNSCs, Ac 5 ManNTProp upregulated biochemical endpoints consistent with Wnt signaling in the absence of a thiol-reactive scaffold. In the hASCs, both Ac 5 ManNTProp and Ac 5 ManNTBut suppressed adipogenic differentiation, with Ac 5 ManNTBut providing a more potent response, and they did not interfere with differentiation to a glial lineage (Schwann cells). These results expand the horizon for using MGE in regenerative medicine by providing new tools (Ac 5 ManNTProp and Ac 5 ManNTBut) for manipulating human stem cells.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.